NCNeng Cao

Neng Cao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Neng Cao has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Juan Ni

    School of Life Sciences, The Engineering Research Center of Sustainable Development and Utilization of Biomass Energy, Ministry of Education, Yunnan Normal University, Kunming, Yunnan 650500, China

    1 shared publication
  • Tao Zhou

    School of Life Sciences, The Engineering Research Center of Sustainable, Development and Utilization of Biomass Energy, Yunnan Normal University, Kunming 650500, China

    1 shared publication
  • Tianning Zhou

    Department of Breast Disease, Yunnan Tumor Hospital, Kunming, 650118, China

    1 shared publication
  • Weijiang Xu

    School of Life Sciences, The Engineering Research Center of Sustainable Development and Utilization of Biomass Energy, Ministry of Education, Yunnan Normal University, Kunming, Yunnan 650500, China

    1 shared publication
  • Xiayu Wu

    School of Life Sciences, Yunnan Normal University, Kunming, China

    1 shared publication
  • Xu Wang

    School of Life Sciences, The Engineering Research Center of Sustainable Development and Utilization of Biomass Energy, Yunnan Normal University, Kunming 650500, China.

    1 shared publication

Latest Publications

  • Open Access

    Plasma homocysteine levels and genetic polymorphisms in folate metablism are associated with breast cancer risk in chinese women

    by Xiayu Wu, Tianning Zou, Neng Cao, Juan Ni, Weijiang Xu, Tao Zhou, Xu Wang

    Background: Folate plays a pivotal role in DNA synthesis, repair, methylation and homocysteine (Hcy) metabolism. Therefore, alterations in the folate-mediated one-carbon metabolism may lead to abnormal methylation proliferation, increases of tumor/neoplasia and vein thrombosis/cardiovascular risk. The serine hydroxymethyhransferase (SHMT), methionine synthase (MS), methionine synthase reductase (MTRR) and cystathionine beta synthase (CBS) regulate key reactions in the folate and Hcy metabolism. Therefore, we investigated whether the genetic variants of theSHMT, MS, MTRRandCBS gene can affect plasma Hcy levels and are associated with breast cancer risk.Methods: Genotyping was performed by PCR-RFLP method. Plasma Hcy levels were measured by the fluorescence polarization immunoassay on samples of 96 cases and 85 controls.Results: (a) TheSHMT 1420 T, MS 2756G, MTRR 66Gallele frequency distribution showed significant difference between case and controls (p < 0.01 ~ 0.05). (b) The concentration of plasma Hcy levels ofSHMT 1420TTwas significantly lower than that of the wild type, while the plasma Hcy levels ofMS 2756GG,CBS 699TT/1080TTsignificantly higher than that of the wild type both in case and controls. The plasma Hcy levels ofMTRR 66GGwas significantly higher than that of wild type in cases. The plasma Hcy levels of the same genotype in cases were significantly higher than those of controls exceptSHMT 1420CC, MS 2756AA, MTRR 66GG; (c) Multivariate Logistic regression analysis showed thatSHMT C1420T(OR = 0.527, 95% CI = 0.55 ~ 1.24),MS A2756G(OR = 2.32, 95% CI = 0.29 ~ 0.82),MTRR A66G(OR = 1.84, 95% CI = 0.25 ~ 1.66) polymorphism is significantly associated with breast cancer risk. And elevated plasma Hcy levels were significantly linked to increased risk of breast cancer (adjusted OR = 4.45, 95% CI = 1.89-6.24 for the highest tertile as compared with the lowest tertile).Conclusions: The current study results seem to suggest a possibility that SHMT C1420Tmutation may be negatively correlated with breast cancer susceptibility; whileMS A2756GandMTRR A66Gmutation may be positively associated with breast cancer risk.SHMT C1420T, MS A2756G, MTRR A66G, CBS C1080T, CBS C699Tlocus mutation may be factors affecting plasma levels of Hcy. The plasma Hcy levels could be metabolic risk factor for breast cancer risk to a certain extent.